Suppr超能文献

孕前促甲状腺激素对育龄人群产科结局的影响。

Impact of preconception thyrotrophin on obstetric outcomes in the fertile population.

作者信息

Ortiz María Inés, Carrizo Carolina, Russo Picasso María Fabiana, Otaño Lucas, Knoblovits Pablo

机构信息

Servicio de Endocrinología Metabolismo y Medicina Nuclear, Hospital Italiano de Buenos Aires, CABA, Buenos Aires, Argentina.

Servicio de Endocrinología Metabolismo y Medicina Nuclear, Hospital Italiano de Buenos Aires, CABA, Buenos Aires, Argentina.

出版信息

Endocrinol Diabetes Nutr (Engl Ed). 2023 Apr;70(4):262-269. doi: 10.1016/j.endien.2023.03.014. Epub 2023 Apr 4.

Abstract

INTRODUCTION

There is evidence that subclinical hypothyroidism is associated with infertility, miscarriage and obstetric complications. However, there is controversy regarding the optimal TSH value in women seeking pregnancy. Current guidelines recommend that hypothyroid women with levothyroxine replacement who are planning pregnancy should optimise the dose of levothyroxine to achieve thyrotrophin (TSH) levels <2.5 mU/l, since these requirements increase in pregnancy, thus reducing the risk of TSH elevation during the first trimester. In women with infertility, who undergo highly complex treatments and have positive thyroid autoimmunity, values of TSH <2.5 mU/l prior to fertility treatment are suggested. Although this is a different population, these «optimal» TSH levels were also extended to euthyroid women without evidence of infertility, who are seeking pregnancy.

OBJECTIVES

Determine whether preconception TSH levels between 2.5 and 4.64 mIU/l are associated with adverse obstetric outcomes in euthyroid women.

MATERIALS AND METHODS

Retrospective cohort study. We evaluated 3265 medical records of pregnant women aged 18-40 years, euthyroid (TSH 0.5-4.64 mU/ml), with TSH measurement at least one year before gestation. 1779 met inclusion criteria. The population was divided according to categories: TSH 0.5-2.4 mU/l (optimal) and TSH 2.5-4.6 mU/l (suboptimal). Information on maternal and fetal obstetric outcomes was collected from each group.

RESULTS

We found no statistical difference in the occurrence of adverse obstetric events between the two groups. There was also no difference when adjusting for thyroid autoimmunity, age, body mass index, previous diabetes and previous arterial hypertension.

CONCLUSION

Our results suggest that the reference range of TSH used in the general population could be used in women seeking pregnancy, even in the presence of thyroid autoimmunity. Treatment with levothyroxine should be considered only in patients with special situations.

摘要

引言

有证据表明亚临床甲状腺功能减退与不孕、流产及产科并发症有关。然而,对于备孕女性的最佳促甲状腺激素(TSH)值存在争议。当前指南建议,计划怀孕且正在接受左甲状腺素替代治疗的甲状腺功能减退女性应优化左甲状腺素剂量,以使促甲状腺素(TSH)水平<2.5 mU/l,因为孕期这些需求会增加,从而降低孕早期TSH升高的风险。对于接受高度复杂治疗且甲状腺自身免疫呈阳性的不孕女性,建议在生育治疗前TSH值<2.5 mU/l。尽管这是不同人群,但这些“最佳”TSH水平也扩展至无不孕证据且正在备孕的甲状腺功能正常女性。

目的

确定甲状腺功能正常女性孕前TSH水平在2.5至4.64 mIU/l之间是否与不良产科结局相关。

材料与方法

回顾性队列研究。我们评估了3265例年龄在18至40岁、甲状腺功能正常(TSH 0.5至4.64 mU/ml)且在妊娠前至少一年进行过TSH测量的孕妇的病历。1779例符合纳入标准。根据类别将人群分为:TSH 0.5至2.4 mU/l(最佳)和TSH 2.5至4.6 mU/l(次优)。从每组收集母婴产科结局信息。

结果

我们发现两组之间不良产科事件的发生率无统计学差异。在调整甲状腺自身免疫、年龄、体重指数、既往糖尿病和既往动脉高血压后也无差异。

结论

我们的结果表明,一般人群中使用的TSH参考范围可用于备孕女性,即使存在甲状腺自身免疫。仅在特殊情况的患者中应考虑左甲状腺素治疗。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验